Zai Lab (ZLAB) Share-based Compensation (2017 - 2026)
Zai Lab (ZLAB) posted quarterly Share-based Compensation of $13.5 million for Q1 2026, down 14.41% year-on-year from $15.8 million in Q1 2025, and down 14.95% on a QoQ basis from $15.9 million in Q4 2025.
Zai Lab (ZLAB) Share-based Compensation (2017 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Share-based Compensation for 10 consecutive years, with $13.5 million the latest figure, recorded in Q1 2026.
- Quarterly Share-based Compensation fell 14.41% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.3 million (down 7.52% YoY) and the FY2025 annual result came in at $65.6 million, down 7.15% from the prior year.
- Share-based Compensation eased to $13.5 million in Q1 2026 per ZLAB's latest filing, from $15.9 million in the prior quarter.
- Over the last five years, Share-based Compensation for ZLAB reached as high as $22.0 million in Q3 2023 and fell as low as $12.4 million in Q1 2022.
- A 5-year average of $17.1 million and a median of $16.9 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 81.02% — and 2024, when it slipped 23.63%.
- Year by year, Share-based Compensation stood at $15.6 million in 2022, then surged by 31.56% to $20.5 million in 2023, then fell by 15.79% to $17.2 million in 2024, then retreated by 7.75% to $15.9 million in 2025, then declined by 14.95% to $13.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $13.5 million, $15.9 million, and $16.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn | 13.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.52 Mn |
| Mar 31, 2026 | 13.52 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2025 | 16.92 Mn |
| Sep 30, 2025 | 16.92 Mn |
| Jun 30, 2025 | 16.97 Mn |
| Jun 30, 2025 | 16.97 Mn |
| Mar 31, 2025 | 15.80 Mn |
| Mar 31, 2025 | 15.80 Mn |
| Dec 31, 2024 | 17.24 Mn |
| Dec 31, 2024 | 17.24 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Sep 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 18.64 Mn |
| Jun 30, 2024 | 18.64 Mn |
| Mar 31, 2024 | 17.98 Mn |
| Mar 31, 2024 | 17.98 Mn |
| Dec 31, 2023 | 20.47 Mn |
| Dec 31, 2023 | 20.47 Mn |